Patents by Inventor Jonathan Mark Hexham

Jonathan Mark Hexham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunotoxin fusion proteins and means for expression thereof
    Patent number: 8987426
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: March 24, 2015
    Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, Novartis AG
    Inventors: David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF
    Publication number: 20130211049
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be ex-pressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: April 10, 2012
    Publication date: August 15, 2013
    Applicants: Office of Technology Transfer
    Inventors: David M. Neville, JR., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • Immunotoxin fusion proteins and means for expression thereof
    Patent number: 8217158
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Grant
    Filed: March 5, 2010
    Date of Patent: July 10, 2012
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF
    Publication number: 20110086416
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: March 5, 2010
    Publication date: April 14, 2011
    Applicant: The Government of the US, as Represented by the Secretary, Department of Health and Human Services
    Inventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • Immunotoxin fusion proteins and means for expression thereof
    Patent number: 7696338
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: April 13, 2010
    Assignees: The United States of America as represented by the Department of Health and Human Services, Novartis AG
    Inventors: David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
  • Immunotoxin fusion proteins and means for expression thereof
    Publication number: 20040127682
    Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: January 13, 2004
    Publication date: July 1, 2004
    Inventors: David M Neville, Jerry T Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan